Compound ProfileRetatrutide 10mg — mechanism, research applications & compound data
Retatrutide (LY3437943) — often shortened by researchers to "Reta" — is the most advanced triple-agonist research peptide currently in clinical development, simultaneously targeting the GLP-1, GIP and glucagon receptors. Peptides UK supplies pharmaceutical-grade Retatrutide 10mg lyophilised powder, independently HPLC-verified to ≥98% purity and shipped same-day from Manchester with a batch-matched Certificate of Analysis.
01
Buy Retatrutide UK — is "Reta" the same compound?
Yes. "Reta" is simply the informal shorthand the research community uses for Retatrutide — the two terms refer to the exact same triple GLP-1/GIP/glucagon receptor agonist (LY3437943). Whether you're searching "retatrutide uk", "buy retatrutide uk", "retatrutide for sale uk", "retatrutide peptide uk" or simply "buy reta", this 10mg vial is Peptides UK's standard retatrutide listing — dispatched same-day from Manchester with full batch traceability and a ≥98% HPLC-verified, CoA-backed Certificate of Analysis. We also stock a separate Retatrutide 20mg vial for laboratories running extended, longer-duration protocols.
02
What is Retatrutide and why is it significant in metabolic research?
Retatrutide is a novel synthetic peptide developed by Eli Lilly as the first investigational triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. Unlike single-agonist incretin mimetics such as semaglutide or dual agonists such as tirzepatide, retatrutide engages all three metabolic receptors in parallel — producing a markedly broader signalling profile in in-vitro models of energy expenditure, adipogenesis and hepatic lipid metabolism. Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) reported a mean 17.5% body weight reduction at 24 weeks at the highest dose cohort, positioning retatrutide as the most potent investigational compound in its class. Phase 3 trials commenced in 2023.
03
Retatrutide mechanism of action: triple-receptor agonism explained
GLP-1 receptor agonism slows gastric emptying and enhances glucose-dependent insulin secretion in pancreatic beta-cell models. GIP receptor agonism amplifies postprandial insulin release and modulates adipocyte lipid storage. Glucagon receptor agonism increases hepatic glucose output and, critically, drives energy expenditure and lipolysis. By converging all three receptor pathways into a single molecule with a fatty-acid moiety for extended half-life, retatrutide produces a synergistic metabolic profile not achievable with mono- or dual-agonist peptides. This makes it a uniquely important compound for in-vitro receptor pharmacology, GPCR signalling studies and adipose-tissue research models.
04
Research applications for Retatrutide 10mg
The 10mg vial supports a wide range of preclinical and in-vitro research designs, including GLP-1/GIP/glucagon receptor binding assays, cAMP/β-arrestin recruitment studies, adipocyte differentiation and lipolysis modelling, hepatocyte glucose-output assays, mitochondrial biogenesis and thermogenesis pathway research, comparative incretin receptor pharmacology versus semaglutide and tirzepatide, and pharmacokinetic modelling of fatty-acid-acylated peptide analogues. Researchers comparing single-, dual- and triple-agonist signalling profiles routinely use this compound as the reference triple-agonist standard.
05
Reconstitution, dosing volumes and handling for Retatrutide
Reconstitute the lyophilised powder with bacteriostatic water (0.9% benzyl alcohol). Add solvent slowly down the inside wall of the vial — never inject directly onto the lyophilised cake. Allow the powder to dissolve gently at room temperature for 60–90 seconds; do not shake. A common reconstitution volume is 1ml or 2ml of bacteriostatic water per 10mg vial depending on research protocol concentration. Once reconstituted, the solution must be refrigerated at 2–8°C and used within 28 days. Do not refreeze. Always allow the unopened lyophilised vial to reach room temperature before puncturing the septum to prevent condensation entering the vial and compromising stability.
06
Quality assurance and Certificate of Analysis
Every Retatrutide 10mg lot dispatched by Peptides UK is independently analysed by Janoshik Analytical or Aspen Bioanalytics — two of Europe's most respected third-party peptide testing laboratories. Each batch is tested for HPLC-UV purity (≥98%), mass-spectrometry identity confirmation against the published molecular weight of 4,810.5 Da, residual solvent profile, and visual integrity. The signed PDF Certificate of Analysis for the exact lot you receive is downloadable directly from this product page — not a generic placeholder, not a marketing summary. Lot traceability is auditable.
07
Why UK researchers choose Peptides UK for Retatrutide
Peptides UK is a fully UK-based research peptide supplier headquartered in Manchester. We hold stock in temperature-controlled storage, dispatch the same working day for orders placed before 6pm GMT, ship via Royal Mail Tracked 24 in insulated mailers with ice packs, and provide signed batch CoAs from independent laboratories on every vial. No grey-market sourcing, no overseas customs delays, no fabricated documentation — just verifiable analytical data on UK-stocked research compounds at competitive prices.